ArticleEuropean journal of epidemiology2026
Global disparities in realized stroke prevention attributable to antihypertensive treatment: a population-level analysis of 198 countries, 1990-2019.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clarifying statistical methods in a TriNetX analysis of statins and osteoporosis in CKD patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Although antihypertensive treatment reduces stroke risk, it remains unclear whether advances in hypertension management have translated into equitable stroke prevention at the population level. We quantified realized stroke prevention attributable to antihypertensive treatment in adults aged 30-79 years across 198 countries from 1990 to 2019. In this population-level modelling analysis, we integrated country-, sex-, age-, and year-specific estimates of hypertension prevalence and treatment coverage with stroke incidence data to derive the prevented fraction for the population (PFP), defined as the proportion of strokes averted under observed treatment patterns relative to a no-treatment counterfactual. We compared PFP across sex, age, and World Bank income groups and summarized temporal trends using average annual percentage change and age-period-cohort analyses. From 1990 to 2019, median PFP increased globally from 8.8% (interquartile range, 4.9-11.1) to 15.9% (10.8-19.5) in women and from 5.1% (2.7-6.5) to 11.8% (7.7-15.3) in men, corresponding to an estimated 0.96 million model-estimated strokes averted in 2019. Although low-income countries showed the fastest annual increases, their 2019 PFP remained about half that of high-income countries. Women consistently had higher PFP than men. PFP remained low in older adults and was similarly low, or lower, in adults aged 30-34 years. These findings indicate that antihypertensive treatment has corresponded to substantial but uneven model-estimated stroke prevention worldwide, with persistent disparities by national income, sex, and age group.
Indexed as
Identifiers
42470586What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.